STREAM (Standardised Treatment Regimens of Anti-tuberculosis drugs for Multidrug-Resistant Tuberculosis) Stage 1 demonstrated non-inferior efficacy of a short regimen for rifampicin-resistant TB (RR-TB) compared to a long regimen as recommended by the World Health Organization. This study analyzed factors associated with a definite or probable failure or relapse (FoR) event in participants receiving the short regimen. The factors associated with FoR outcomes identified in this study should be considered when determining the optimal shortened treatment regimen.
Published: August 1, 2022
Sign up to receive our monthly Research Roundup email, which offers a selection of new public health research from major journals.
Recent Abstracts
Catalyzing Support for CRVS Improvement – Examples from the Data for Health Initiative
A Guide to Designing Contextualized Civil Registration and Vital Statistics E-Learning Courses
Guide to Developing Standard Operating Procedures (SOPs) for Civil Registration Using a Case-Based…
Building Safe and Healthy Communities
Uncovering the Hidden Risks of PM 2.5 Exposure Among School-Aged Children in Jakarta
Foundations & Futures: Reimagining Public Health in the Artificial Intelligence Era
Strengthening Health Systems to Address Air Pollution in Ethiopia
Policy Brief: Childhood Blood Lead Surveillance in Indonesia – Findings and Policy Recommendations
Impact of Blue Lanes on Road Safety: Crashes, Speed and Motorcyclists’ Perceptions in…
Impacto da Faixa Azul na Segurança Viária: Sinistros, velocidade e percepções de motociclistas…